Predicting mortality and adverse events in patients with advanced pancreatic cancer treated with palliative gemcitabine-based chemotherapy in a multicentre phase III randomized clinical trial: the APC-SAKK risk scores

Piera Gargiulo, Daniel Dietrich, Richard Herrmann, György Bodoky, Thomas Ruhstaller, Werner Scheithauer, Bengt Glimelius, Simona Berardi, Sandro Pignata, Peter Brauchli, Piera Gargiulo, Daniel Dietrich, Richard Herrmann, György Bodoky, Thomas Ruhstaller, Werner Scheithauer, Bengt Glimelius, Simona Berardi, Sandro Pignata, Peter Brauchli

Abstract

Background: The prognosis of advanced pancreatic cancer (APC) is poor and differs considerably among patients. Therefore, it is clinically relevant to identify patients with APC who are more likely to benefit from palliative chemotherapy with reduced risk of toxicity. To date, there is no prognostic score universally recommended to help clinicians in planning the therapeutic management.

Methods: Using individual patient data from 319 cases of APC treated with gemcitabine-based chemotherapy and enrolled in the SAKK 44/00-CECOG/PAN.1.3.001 randomized trial, several baseline variables, including inflammatory markers, were analysed post hoc as predictors of mortality and/or grade 3 or 4 chemotherapy-related toxicity and separate risk scores were developed.

Results: Median survival of the study patients was 7.9 months (interquartile range 3.7-13.3 months). Independent predictors of mortality included increased Aspartate transaminase (ASAT), low performance status, increased derived neutrophil to lymphocyte ratio, increased Carbohydrate Antigen 19-9 (CA 19-9), low haemoglobin, presence of pain, presence of metastasis and increased alkaline phosphatase (ALP). During the study, 117 patients experienced at least one grade 3 or 4 adverse event. Independent predictors of toxicity included white blood cells, ALP, renal function and bilirubin levels at baseline. Both models displayed moderate levels of discrimination (C-statistic 0.68 and 0.64 for mortality and toxicity, respectively) and adequate calibration.

Conclusions: We developed simple-to-use prognostic scores for mortality and severe toxicity for patients with APC. These scores can be useful in daily practice to identify patients with increased risk of death or toxicity and to plan the most appropriate therapeutic strategy to improve survival and quality of life. Further prospective studies to validate such scores are needed.

Keywords: advanced pancreatic cancer; chemotherapy; inflammatory markers; mortality; prediction score; toxicity.

Conflict of interest statement

Conflict of interest statement: The authors declare no conflicts of interest in preparing this article.

Figures

Figure 1.
Figure 1.
Predictors of mortality. ASAT, aspartate transaminase; CA 19-9, carbohydrate antigen 19-9; dNLR, derived neutrophil to lymphocyte ratio.
Figure 2.
Figure 2.
Score for mortality.
Figure 3.
Figure 3.
Score for toxicity.

References

    1. Kamisawa T, Wood LD, Itoi T, et al. Pancreatic cancer. Lancet 2016; 388: 73–85.
    1. Park HS, Lee HS, Park JS, et al. Prognostic scoring index for patients with metastatic pancreatic adenocarcinoma. Cancer Res Treat 2016; 48: 1253–1263.
    1. Kou T, Kanai M, Yamamoto M, et al. Prognostic model for survival based on readily available pretreatment factors in patients with advanced pancreatic cancer receiving palliative chemotherapy. Int J Clin Oncol 2016; 21: 118–125.
    1. Ter Veer E, van Rijssen LB, Besselink MG, et al. Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease. Lancet Oncol 2018; 19: e151–e160.
    1. Mei Z, Shi L, Wang B, et al. Prognostic role of pretreatment blood neutrophil-to-lymphocyte ratio in advanced cancer survivors: a systematic review and meta-analysis of 66 cohort studies. Cancer Treat Rev 2017; 58: 1–13.
    1. van Soest RJ, Templeton AJ, Vera-Badillo FE, et al. Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials. Ann Oncol 2015; 26: 743–749.
    1. Watt DG, Proctor MJ, Park JH, et al. The Neutrophil-Platelet Score (NPS) predicts survival in primary operable colorectal cancer and a variety of common cancers. PLoS One 2015; 10: e0142159.
    1. Herrmann R, Bodoky G, Ruhstaller T, et al. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol 2007; 25: 2212–2217.
    1. Bernhard J, Dietrich D, Scheithauer W, et al. Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial–SAKK 44/00-CECOG/PAN.1.3.001. J Clin Oncol 2008; 26: 3695–3701.
    1. Hess V, Glimelius B, Grawe P, et al. CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial. Lancet Oncol 2008; 9: 132–138.
    1. Ueno H, Okada S, Okusaka T, et al. Prognostic factors in patients with metastatic pancreatic adenocarcinoma receiving systemic chemotherapy. Oncology 2000; 59: 296–301.
    1. Tabernero J, Chiorean EG, Infante JR, et al. Prognostic factors of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer. Oncologist 2015; 20: 143–150.
    1. Geng M, Xu H, Ren R, et al. Prognostic value of clinicopathological characteristics in patients with pancreatic cancer. Chin J Cancer Res 2015; 27: 509–515.
    1. Papadoniou N, Kosmas C, Gennatas K, et al. Prognostic factors in patients with locally advanced (unresectable) or metastatic pancreatic adenocarcinoma: a retrospective analysis. Anticancer Res 2008; 28: 543–549.
    1. Vernerey D, Huguet F, Vienot A, et al. Prognostic nomogram and score to predict overall survival in locally advanced untreated pancreatic cancer (PROLAP). Br J Cancer 2016; 115: 281–289.
    1. Xue P, Kanai M, Mori Y, et al. Neutrophil-to-lymphocyte ratio for predicting palliative chemotherapy outcomes in advanced pancreatic cancer patients. Cancer Med 2014; 3: 406–415.
    1. Kasuga A, Okano N, Naruge D, et al. Retrospective analysis of fixed dose rate infusion of gemcitabine and S-1 combination therapy (FGS) as salvage chemotherapy in patients with gemcitabine-refractory advanced pancreatic cancer: inflammation-based prognostic score predicts survival. Cancer Chemother Pharmacol 2015; 75: 457–464.
    1. Luo G, Guo M, Liu Z, et al. Blood neutrophil-lymphocyte ratio predicts survival in patients with advanced pancreatic cancer treated with chemotherapy. Ann Surg Oncol 2015; 22: 670–676.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다